POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naive Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

被引：0

作者：

Vachhani, Pankit ^{[1
]}

Rampal, Raajit ^{[2
]}

Bradley, Terrence ^{[3
]}

Harrison, Claire ^{[4
]}

Jain, Tania ^{[5
]}

Kuykendall, Andrew T. ^{[6
]}

Palandri, Francesca ^{[7
]}

Mascarenhas, John O. ^{[8
]}

Al-Ali, Haifa Kathrin ^{[9
]}

Passamonti, Francesco ^{[10
,11
]}

Nekhymchuk, Anna ^{[12
]}

Foss, Hilarie

Rothbaum, Wayne ^{[12
]}

Verstovsek, Srdan ^{[12
]}

Heidel, Florian ^{[13
]}

机构：

[1] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY USA

[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[4] Guys & St Thomas NHS Fdn Trust, London, England

[5] Johns Hopkins Univ, Baltimore, MD USA

[6] Univ S Florida, Moffitt Canc Ctr, Tampa, FL USA

[7] IRCCS Azienda Osped Univ Bologna, Policlin S Orsola Malpighi, Ist Ematol Serygnoli, Bologna, Italy

[8] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[9] Univ Hosp Halle, Halle, Saale, Germany

[10] Fdn IRCCS CaGranda Osped Maggiore Policlin Milano, Dept Pathophysiol & Transplantat, Milan, Italy

[11] Univ Milan, Dipartimento Oncol & Oncoematol, Milan, Italy

[12] Kartos Therapeut Inc, Redwood City, CA USA

[13] Hannover Med Sch, Hannover, Germany

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-200966

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：18083 / 18084

页数：2

共 50 条

[41] Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study
Khodaie-Ardakani, Mohammad-Reza
Mirshafiee, Omid
Farokhnia, Mehdi
Tajdini, Masih
Hosseini, Seyed-Mohammad-Reza
Modabbernia, Amirhossein
Rezaei, Farzin
Salehi, Bahman
Yekehtaz, Habibeh
Ashrafi, Mandana
Tabrizi, Mina
Akhondzadeh, Shahin
PSYCHIATRY RESEARCH, 2014, 215 (03) : 540 - 546
[42] Memantine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia Randomized, Double-Blind, Placebo-Controlled Study
Rezaei, Farzin
Mohammad-karimi, Maryam
Seddighi, Sahar
Modabbernia, Amirhossein
Ashrafi, Mandana
Salehi, Bahman
Hammidi, Siran
Motasami, Hamid
Hajiaghaee, Reza
Tabrizi, Mina
Akhondzadeh, Shahin
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2013, 33 (03) : 336 - 342
[43] Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures
Wu, Xun-Yi
Hong, Zhen
Wu, Xun
Wu, Li-Wen
Wang, Xue-Feng
Zhou, Dong
Zhao, Zhong-Xin
Lv, Chuan-Zhen
EPILEPSIA, 2009, 50 (03) : 398 - 405
[44] Efficacy and Safety of Pioglitazone Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-controlled Study
Cho, Yun Kyung
Kim, Kyung-Soo
Lee, Byung-Wan
Hong, Jun Hwa
Yu, Jae Myung
Lim, Soo
Kim, Ye An
Lee, Chang Beom
Kim, Sang Soo
Kwak, Soo Heon
Lee, Woo Je
CLINICAL THERAPEUTICS, 2024, 46 (09) : 662 - 669
[45] Diacerein for the treatment of rheumatoid arthritis in patients with inadequate response to methotrexate: a pilot randomized, double-blind, placebo-controlled add-on trial
Louthrenoo, Worawit
Nilganuwong, Surasak
Nanagara, Ratanavadee
Siripaitoon, Boonjing
Basset, Sabine Collaud
CLINICAL RHEUMATOLOGY, 2019, 38 (09) : 2461 - 2471
[46] Diacerein for the treatment of rheumatoid arthritis in patients with inadequate response to methotrexate: a pilot randomized, double-blind, placebo-controlled add-on trial
Worawit Louthrenoo
Surasak Nilganuwong
Ratanavadee Nanagara
Boonjing Siripaitoon
Sabine Collaud Basset
Clinical Rheumatology, 2019, 38 : 2461 - 2471
[47] Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Jabbour, Serge A.
Hardy, Elise
Sugg, Jennifer
Parikh, Shamik
DIABETES CARE, 2014, 37 (03) : 740 - 750
[48] ISIS 449884 Injection Add-On to Metformin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Study
Ji, Linong
Gao, Leili
Feng, Zhikai
Chen, Guoliang
Fu, Jing
Morgan, Erin
Bhanot, Sanjay
Gao, Shan
Zhang, Hongyan
Liang, Zicai
Gan, Li
DIABETES THERAPY, 2024, 15 (10) : 2183 - 2196
[49] Effect of the Selective Norepinephrine Reuptake Inhibitor Reboxetine on Cognitive Dysfunction in Schizophrenia Patients: An Add-on, Double-Blind Placebo-Controlled Study
Poyurovsky, Michael
Faragian, Sarit
Fuchs, Camil
Pashinian, Artashez
ISRAEL JOURNAL OF PSYCHIATRY AND RELATED SCIENCES, 2009, 46 (03): : 213 - 220
[50] Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)
Pardanani, Animesh
Harrison, Claire N.
Cortes, Jorge E.
Cervantes, Francisco
Mesa, Ruben A.
Milligan, Donald
Masszi, Tamas
Mishchenko, Elena
Jourdan, Eric
Vannucchi, Alessandro M.
Drummond, Mark
Jurgutis, Mindaugas
Kuliczkowski, Kazimierz
Gheorghita, Emanuil
Passamonti, Francesco
Neumann, Frank
Gao, Guozhi
Tefferi, Ayalew
BLOOD, 2013, 122 (21)

← 1 2 3 4 5 →